TB-500 vs Solensia for Dogs: How They Differ

Is TB-500 better than Solensia?

No — and the comparison itself is built on a mismatch. Solensia is a prescription monoclonal antibody licensed for cats, not dogs; the canine product in the same drug class is Librela. Both work on pain signalling. TB-500 is a peptide, used by owners as part of soft-tissue and mobility recovery support, and it works on a completely different biological process. Asking which is "better" is like asking whether a splint is better than an anaesthetic. They do different jobs, and for a lot of dogs the honest answer is that the two lanes don't compete at all.

Here is what each one actually is, what happens in the body when it's used, and how owners decide what belongs in their dog's recovery plan.

The Solensia mix-up worth clearing up first

Solensia is the brand name for frunevetmab, an anti-nerve-growth-factor monoclonal antibody approved by the FDA for the control of pain associated with osteoarthritis in cats. Librela is bedinvetmab, the same class of antibody engineered for dogs, approved for the control of osteoarthritis pain in dogs. Both come from the same manufacturer, both are prescription-only, and both are given by injection at the clinic on a schedule your veterinarian sets.

So if you searched "Solensia for dogs," one of two things is true. Either you saw the cat product and wondered whether there was a dog version — there is, and it's Librela — or your vet mentioned a monthly injection for arthritis pain and the brand names blurred together. Either way, the comparison people are really trying to make is: should I be looking at a prescription pain injection, or at a repair-support peptide?

That's a much better question, and it has a real answer.

What an anti-NGF antibody does inside an arthritic joint

Nerve growth factor is a signalling protein. In a healthy joint it sits in the background. In an osteoarthritic joint, inflammation drives NGF levels up, and NGF sensitises the nerve endings that supply the joint capsule and surrounding tissue. The nerves become easier to trigger. Movements that shouldn't hurt start hurting, and the dog offloads the limb, which is where the muscle wasting and the cautious, stiff gait come from.

An anti-NGF monoclonal antibody is a large, targeted protein that binds circulating NGF so it can't reach those receptors. Turn the volume down on the signal, and the dog's experience of pain changes. That is a genuinely elegant mechanism and, for the right dog, a valuable one.

What it is not is a structural intervention. The antibody does not rebuild cartilage, reorganise collagen in a healing ligament, or improve blood supply to a repairing tendon. It is analgesia — sophisticated, long-acting analgesia — and it is prescribed, dosed and monitored by a veterinarian who has examined your dog, ruled out other causes of lameness, and weighed the risks. If your vet has recommended it, that recommendation is theirs to make and yours to discuss with them. Nothing in this article is a reason to decline it or to stop it.

What TB-500 does — the actin side of tissue repair

TB-500 is a synthetic peptide corresponding to an active region of thymosin beta-4, a small protein that occurs naturally in most mammalian cells and appears in high concentrations in wound fluid and platelets. Thymosin beta-4's best-characterised job is binding actin — the protein filament system cells use to change shape and crawl.

That matters more than it sounds. Repair is a migration problem before it is anything else. Fibroblasts, endothelial cells and progenitor cells have to physically travel into the injured zone, and they travel by remodelling their actin cytoskeleton. Research on thymosin beta-4 describes roles in cell migration, in the formation of new microvessels, and in modulating the inflammatory phase of wound repair in laboratory and animal models. Owners choose TB-500 because that mechanism sits exactly where a healing tendon, ligament or muscle needs help — in the phase where cells have to arrive and organise.

BPC-157 is the peptide TB-500 is most often paired with. It is a synthetic sequence derived from a protein found in gastric juice, and preclinical research describes effects on tendon and ligament healing models, on growth-factor receptor expression, and on angiogenic signalling — the formation of the new capillary beds that carry oxygen and nutrients into repairing tissue. Tendons and ligaments are notoriously poorly vascularised, which is a large part of why they heal slowly and imperfectly.

The two peptides are stacked because they act on adjacent arms of the same process rather than duplicating each other: broadly, TB-500 on cell migration and vascular sprouting, BPC-157 on collagen organisation and growth-factor signalling. That's the reasoning behind combining them in a single formulation such as K9-REPAIR, which pairs BPC-157 with TB-500 in weight-based dosing.

None of this is a promise about your dog. BPC-157 and TB-500 are not FDA-approved veterinary drugs, the evidence base is largely preclinical, and what exists is mechanistic and animal-model work plus what owners report through recovery. That is emerging science that a lot of owners are choosing to adopt, and the mechanism is specific enough to explain why.

Side by side: pain signalling versus repair support

Read down that table and the incompatibility disappears. One column is about how a joint feels. The other is about what happens in tissue that is trying to rebuild.

Which question are you actually trying to answer?

Start with the problem, not the product.

If pain is the primary problem — an older dog with radiographically confirmed osteoarthritis, reluctant on stairs, slow to rise, guarding a hip — that is a diagnosis-and-prescription conversation. Anti-NGF therapy, NSAIDs, adjunct analgesics and a rehab plan all live in your veterinarian's territory. Peptides are not a substitute for any of them, and no responsible reading of the science says otherwise.

If tissue is the primary problem — a cruciate repair with a defined post-op timeline, a strained iliopsoas, a shoulder that keeps flaring in a working dog, a soft-tissue injury that keeps almost resolving — the question changes. You're no longer asking how to quiet a pain signal. You're asking what the healing environment looks like over the weeks that collagen is laid down and remodelled. That's the lane peptides are chosen for.

Pain control and repair support are two different jobs, and choosing between them is usually the wrong question. Plenty of owners run a vet-directed pain plan and a peptide protocol at the same time, precisely because the mechanisms don't overlap. Tell your veterinarian everything your dog is receiving so they can see the whole picture and flag anything that concerns them.

How to judge a peptide product before you buy

This is where scepticism earns its keep — not aimed at peptides, but at the way they're sold.

The joint aisle is full of kitchen-sink chews: fourteen ingredients on the front, a proprietary blend on the back, and no way to tell how much of anything is actually in there. Fairy-dusting works because owners read the ingredient list and never see the amounts. A long label is not a strong label.

What separates a serious product from a marketing exercise:

• Named actives at disclosed amounts, not a blend hidden behind one number.
• Third-party lab testing with published certificates of analysis, so identity and purity are verified by someone with nothing to gain.
• Weight-based dosing guidance, because a terrier and a mastiff are not the same animal.
• A mechanism the brand can explain in plain English without reaching for outcome promises.
• A return policy that assumes you might not continue — pawgen backs K9-REPAIR with a 60-day money-back guarantee, which is what a brand does when it expects you to judge the product yourself.

Apply the same standard to anything you're already using. Owners moving off a single-mechanism ingredient often find the comparison clarifying.

Key Takeaways

• Solensia is licensed for cats; the anti-NGF antibody for dogs is Librela. If a vet recommended an injection for your dog, it was almost certainly the latter.
• Anti-NGF antibodies target pain signalling. They are prescription analgesia, not structural repair, and that is not a criticism — it is their design.
• TB-500 is based on thymosin beta-4, an actin-binding protein researched for its role in cell migration and new vessel formation during tissue repair.
• BPC-157 and TB-500 are paired because they act on adjacent parts of the same repair sequence; K9-REPAIR combines them with weight-based dosing.
• BPC-157 and TB-500 are not FDA-approved veterinary drugs. The research is mechanistic and preclinical, and owners report using them as part of recovery.
• "Better" depends on the problem. Pain management and repair support are separate jobs and frequently run in parallel.
• Never stop, reduce or skip a prescribed medication to make room for a supplement.

If you're weighing formats and mechanisms more broadly, it's worth reading about undenatured collagen alternatives for dogs and what to consider when switching from undenatured collagen dog supplements, alongside the ingredient breakdown for K9-REPAIR.

One last framing, and it's the one that matters most. Your veterinarian owns the diagnosis and the treatment plan — the imaging, the orthopaedic exam, the prescription decisions, the surgical timeline and the rehab protocol. Nothing here changes that, and no supplement should. Peptides operate in the space that proper veterinary care creates: alongside a real diagnosis, on top of a real plan, with the vet who examined your dog fully informed about everything your dog is taking.

Owners exploring peptide support for their dog can review K9-REPAIR — BPC-157 + TB-500 formulated for dogs — at https://pawgen.com/. BPC-157 and TB-500 are not FDA-approved veterinary drugs. Nothing in this article treats, cures or prevents any condition; every decision about your dog's care belongs with your veterinarian.